Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $12,661.80 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 282 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $12,661.80. Following the sale, the senior vice president now directly owns 133,433 shares of the company’s stock, valued at approximately $5,991,141.70. The trade was a 0.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Paula Green also recently made the following trade(s):

• On Friday, December 6th, Paula Green sold 860 shares of Twist Bioscience stock. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00.
• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $64,656.00.
• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total value of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total transaction of $143,025.10.

Twist Bioscience Trading Down 2.1 %

Shares of Twist Bioscience stock opened at $48.17 on Friday. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -13.38 and a beta of 1.82. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The business’s 50 day simple moving average is $45.61 and its 200-day simple moving average is $46.72.

Wall Street Analysts Forecast Growth

TWST has been the topic of a number of research analyst reports. Scotiabank increased their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Evercore ISI increased their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. TD Cowen reissued a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Wolfe Research initiated coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.90.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in shares of Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after acquiring an additional 526,028 shares during the period. Geode Capital Management LLC boosted its stake in Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after purchasing an additional 26,145 shares during the period. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience during the 3rd quarter valued at about $43,992,000. Wellington Management Group LLP grew its position in Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the last quarter. Finally, Fred Alger Management LLC increased its stake in shares of Twist Bioscience by 17.1% in the third quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock valued at $34,660,000 after purchasing an additional 112,272 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.